Tissue Regenix Group PLC (AIM:TRX), the regenerative medical device company, has signed an exclusive distribution agreement with Joint Operations Ltd for the distribution of the Tissue Regenix OrthoPure XT product in the United Kingdom.
Join Operations is a leading distribution business in the UK, supplying numerous products to treat joint injuries and help to preserve the joints of the body,
The initial agreement is for three years, subject to annual purchase minimums, and Joint Operations will add OrthoPure XT to its portfolio of products.
Joint Operations already distributes orthopaedic equipment to the NHS and the private sector within the UK, offering clinicians comprehensive orthopaedic solutions around joint reconstruction and preservation surgeries.
The OrthoPure XT decellularised xenograft ligament utilises Tissue Regenix's patented dCELL technology and is the only available, non-human biologic graft for certain anterior cruciate ligament reconstruction procedures on the market.
OrthoPure XT can also be used in the reconstruction of other knee ligaments, including multi-ligament and primary procedures when an autograft is not an option.
"We are excited to partner with Joint Operations… This strategic partnership will continue our reach into the UK, ensuring these markets have access to our pioneering medical technology, which will help to transform patient care," said Daniel Lee, chief executive of Tissue Regenix.
Richard Forster, managing director of Joint Operations, commented: "As a company, we spend a great deal of time in ligament reconstructive surgery, and it is tremendously exciting to have a unique xenograft option to offer UK surgeons.
“In particular, we have been impressed by the quality of clinical outcomes being achieved through the Tissue Regenix clinical studies, and we look forward to these results being replicated nationwide over the coming years."